From Breakthrough To Blockbuster Av Donald L. (Fellow In Operations And Technology Management Cambridge Judge Business School And Distinguished Resear

From Breakthrough To Blockbuster Av Donald L. (Fellow In Operations And Technology Management Cambridge Judge Business School And Distinguished Resear

Financial Times Business Top Title March 2022How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world''s most breathtakingly expensive and highly regulated industries?Beginning in the 1970s, several scientific breakthroughs promised to tran......
fra 399,-
Tilgjengelig i 2 butikker
Frakt og levering
Beskrivelse
Financial Times Business Top Title March 2022How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world''s most breathtakingly expensive and highly regulated industries?Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broa
Forhåndsbestill
Frakt og levering
Beskrivelse
Financial Times Business Top Title March 2022How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world''s most breathtakingly expensive and highly regulated industries?Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broader biotech ecosystem that supports them. It paints a portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies, demonstrating how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions.

Produktinformasjon

Utforsk 'From Breakthrough To Blockbuster' Av Donald L.

Er du nysgjerrig på hvordan små selskaper kan konkurrere med de store, mektige aktørene i legemiddelindustrien? I 'From Breakthrough To Blockbuster' av Donald L. får du en fascinerende innsikt i bioteknologibransjens utvikling siden 1970-tallet. Denne boka belyser de vitenskapelige gjennombruddene som revolusjonerte medisinproduksjon og satte ny standard for innovasjon i en bransje preget av strenge reguleringer.

Hva Kan Du Forvente Fra Denne Boka?

  • Innsikt i Bioteknologi: Lær hvordan små bioteknologiselskaper, ofte med færre enn 50 ansatte, har klart å utvikle nesten 40% av de mest betydningsfulle behandlingene for tidligere ubehandlede medisinske behov.
  • Effektiv Innovasjon: Oppdag hvordan miljøet rundt disse selskapene—inkludert akademisk forskning, venturekapital og farmasøytiske samarbeidsprosjekter—har spilt en kritisk rolle i å fremme innovasjon.
  • Kostnadseffektivitet: Boka undersøker hvordan bioteknologiselskaper har oppnådd dette med langt lavere kostnader enn tradisjonelle farmasøytiske selskaper.

Nyttige Perspektiver for Fremtidige Innovatører

Enten du jobber i bioteknologi eller en annen bransje som ønsker å navigere usikre tider, gir 'From Breakthrough To Blockbuster' unike innsikter og strategier for å innovere med suksess.

Ikke gå glipp av denne essensielle lesningen for alle som ønsker å forstå dynamikken mellom små og store aktører innen helsesektoren! Med Donald L. som guide, vil du få både kunnskap og inspirasjon til å løfte din egen virksomhet til nye høyder.

Spesifikasjon

Generelt
Sett
Nei
TypPapirbøker

Pris og prishistorikk

Akkurat nå er 399,- den billigste prisen for From Breakthrough To Blockbuster Av Donald L. (Fellow In Operations And Technology Management Cambridge Judge Business School And Distinguished Resear blant 2 butikker hos Prisradar. Sjekk også vår topp 5-rangering av beste økonomi og ledelse for å være sikker på at du gjør det beste kjøpet.

Prisutvikling:
Stabil
Laveste pris:
300,-
Gjennomsnittspris:
300,-
Høyeste pris:
300,-
Beste tilbudet:
norli.no
Tilgjengelig